Background
Introduction
In mammals, the initial phase of blood production occurs in yolk sac (YS) and is termed primitive haematopoiesis; during this phase, blood cells and large erythroid progenitors with megakaryocyte and macrophages potential can be detected, loosely associated with vascular endothelial cells (the so-called blood islands) [1] . These cells are rapidly replaced by embryonic definitive erythrocytes which are smaller than their primitive counterparts but larger than adult erythrocytes [2] . In humans, until 30 days gestational age (GA), the area surrounding the dorsal aorta, termed the Aorta-Gonad Mesonephros (AGM) region, consists in a matrix with CD146+ vascular endothelial cells capable to generate Haematopoietic Stem Cells (HSCs) with higher self-renewal capacity compared to UCB and adult BM HSCs [3, 4, 5] . The hematopoietic activity in the AGM region precedes that in the embryonic liver, which is colonized around week +7-8 of development and that in the placenta, which acquires HSC activity starting from week +9 of development, long term after the emergence of HSCs in the AGM region [6] . By week+11 well formed arterioles permit cell trafficking and migration and from week +16 hematopoiesis is organized within long bones with areas of fully calcified trabecular bones and areas of dense hematopoiesis [7] .
The relative contribution of each of the above sites to the final pool of adult Hematopoietic Stem Cells (HSC) remains largely unknown and it is believed that none of these sites is accompanied by de novo HSC generation, rather, than these niches support the expansion of migrating HSCs capable of hematopoietic reconstitution, at least starting from AGM region [8] .
HSCs may differ in their properties depending on their location (fetal liver, bone marrow, placenta) and on the age of the fetus; thus, it is important to identify mechanisms that regulate their cell function. The classical hierarchy diagram depicting progenitors arising from an "ideal" HSC provides a simplified view of the hematopoietic system. HSCs may be described more accurately as groups of cells with varying developmental potentials based on intrinsic properties due to their own genetic program and inputs from the cellular niches in which they reside [9] .
Human cord blood (UCB) is a reservoir of a relatively high number of stem cells (HSC, EPC,HSC), with unique functional characteristics probably due to the fact that these cells are neither completely fetal nor adult cells.Its therapeutic use has been proved since 1988, when the first allogeneic HSC transplant was performed; currently, more than 160 public UCB banks have been established worldwide and there are~730 000 UCB units available for public use, mainly for HSC transplant. In addition, an estimated 4.0 million UCB units have been stored for private or family use as guarantee of future application in regenerative medicine and cellular therapies [10] .Despite the extensive characterization of UCB progenitors cells, few studies have examined the properties of preterm and early preterm cord blood cells. These studies have demonstrated that preterm UCB shows a significantly higher concentration of haematopoietic progenitors with increased clonogenic capacity compared to term and an early cellular differentiation, at least in vitro [11, 12, 13] . However, despite the higher proliferative potential, preterm human HSCs demonstrate an impaired homing ability into the NOD/SCID mice, probably due to a lower expression of adhesion molecules [14] .
Preterm birth is associated with high mortality rate and high risk of developing disability. The number of long term complications like bronchopulmonary dysplasia (BPD), retinopathy of prematurity and intracranial hemorrhages, diseases associated to tissue damage, are inversely related to gestational age. Recent insights into pre-clinical studies have focused mainly on potential forms of treatment for BPD, the chronic lung disease of prematurity [15] [16] [17] . In fact, it has been demonstrated that the frequency of ECFCs is directly correlated with the gestational age and that extremely preterm infants, who display lower numbers at birth, have an increased risk of developing BPD due to lung vascular immaturity [18] .In this contest, cord blood-derived stem cells may be a suitable adjuvant therapy for indications in which inflammation and tissue damage occurs.
In this paper, we have studied the functional properties of the umbilical cord blood cells collected from term and preterm neonates in order to establish whether quantitative and qualitative differences exist between the two groups. These cells may be a source of hematopoietic and non-hematopoietic progenitors for immature newborns, to be used for prevent complications related to inflammation, immune disregulation and organ fibrosis.
Materials and Methods

Samples
Cord blood was obtained from umbilical cord vessels of premature and full-term infants of pregnant women immediately after delivery. All participants provide their written informed consent to participate in this study.Exclusion criteria were positivity for HBV, HCV and HIV.
This study was approved by the Ethics Committee of the IRCCS Istituto G. Gaslini, Genoa (N°164 22 th July 2013).The cord blood samples were transferred into the laboratory and analyzed within 12 hours from collection. The definitions of preterm and full term used herein are those adopted by the World Health Organization: <37 weeks gestational age (GA) and 37 weeks GA respectively; conversely, very preterm neonates are defined as having GA <32wks.
Immunophenotypic analysis, side population assay, ALDH activity, and pluripotency gene expression
The enumeration of the hematopoietic progenitor cells (CD34+) was performed by FACS analysis as previously described [19] . After immunofluorescence staining, erythrocytes were lysed with ammonium chloride lysis solution, acquired within one hour by flow cytometry (FACS-CANTO II, BD Biosciences) and analyzed using FlowJo software (TreeStar Inc., Ashland, OR, USA). CD34+ cells were gated according to the modified ISHAGE criteria [20] . Analysis of immature progenitors within CD34 + compartment was performed using antihuman antibodies: VioBlue-CD34 (MiltenyiBiotec), FITC-Lineage Cocktail 1 (lin 1; CD3, CD14, CD16, CD19, CD20, CD56), APC-CD38 (BD) and PE-CD90 (BD Biosciences) [12] Side population (SP) cells were identified in both preterm and term CB as previously described [21] . Mononuclear cells were resuspended at 10 6 cells/mL in warmed staining buffer [DMEM supplemented with 2% fetal calf serum (FCS)] and incubated with 5 μM Dye Cycle Violet (DCV; Molecular Probes Invitrogen Inc.,) for 30 min at 37°C. To set the gates for SP cells, an aliquot of cells was pre-incubated with 50 μM Verapamil (Sigma-Aldrich) for 30 min at 37°C before staining with DCV. At the end of the incubation, cells were labeled with anti-CD34 (BD Biosciences), CD338 (ABCG-2; Miltenyi Biotechnology) and 7-AAD (EBioScience) and subsequently detected on an LSRFortessa flow cytometer (BD Biosciences). Results wereanalyzed using FlowJo software according to the gating strategy previously described [22] .
Aldehyde dehydrogenase (ALDH) activity in HSC was evaluated by using Aldefluor reagent (StemCell Technologies) according to the manufacturer's instructions. Cells were resuspended in aldefluor assay buffer and an appropriate amount of aldefluor substrate was added to 1x10 6 MNCs. Cells were incubated for 30 minutes at 37°C for conversion of substrate to a fluorescent product. An aliquot of Aldefluor-stained cells were immediately treated with diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, to serve as negative control. Aldefluor-substrate labeled cells were then costained with anti-CD34 VioBlue (Miltenyi Biotechnology) and CD38 APC (Bd Biosciences) and subsequently analyzed by FACS.
To evaluate pluripotency gene expression, CD34-stained MNCs were fixed and permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Cells were stained for Nestin, OCT3/4 and Nanog with an PE-conjugated mAb(BD Pharmigen, EBioScience, BD Pharmigen) or isotype controls for 20 minutes at 4°C and then analyzed by flow cytometry.
Clonogenic assays
Methylcellulose-based semisolid assay was used to evaluate Colony Forming Cells (CFCs) [23] . All assays (first and secondary generation colonies) were performed using Methocult H4434 Classic (StemCell TM Technologies, Vancouver BC) which is a methyl-cellulose based medium added with rhSCF, rhGM-CSF,rhIL-3 and rhEPO for the culture of human cells.
First generation: 5μl of whole Cord Blood (WCB) were added to 1 mL semisolid culture medium and plated in duplicate on 24-wells plates. After 14 days of incubation in a humidified atmosphere at 37°C and 5% CO 2 , colonies were evaluated for number and morphology in the same dish using an inverted microscope.Second generation: colonies grown in first generation were collected, pooled and dissociated using Dulbecco's modified Eagle's medium(DMEM,Life Technologies). Nucleated cells (NC) were counted manually and 5x10 4 NC were plated using the same culture conditions of the first generation. The same procedure was performed for the third generation culturing 10 5 NC.
The enumeration of CD 34+ cells was performed by FACS analysis on cells obtained from colony pools(first and second generation).
CD34 positive cell enrichment and RNA isolation
UCB mononuclear cells (MNC) were isolated from fresh heparinized cord blood by density gradient separation and enriched for CD34 + antigen by immune-selection method (Miltenyi Biotech, Germany). Following two cycles on separate columns, CD34 + cell purity was assessed by flow cytometry: only samples ranging between 85% to 95% were selected for RNA extraction. Isolation of total RNA from CD34 + cells was performed with the RNeasyMicroKit (Qiagen AG, Hilden, Germany). RNA obtained was reverse transcribed using the High Capacity RNAto-cDNA Kit according to the manufacturer's instructions and performed on 2720 thermal cycler (Applied Biosystems). RNA isolated from different samples (2-4) was pooled to obtain the amount requested for gene profiling.
TaqMan Array Gene Profiling
TaqMan 1 Gene Expression Assays have been designed using manufacturer's validated bioinformatics pipeline (Applied Biosystems, CA, USA) and consisted in a selected list of target genes (S1 Table) 
Endothelial Colony Forming Cell (ECFC)
ECFC cultures were performed by plating UCB-MNCs (5x10 6 /well) on 6-wells culture dishes coated with collagen (Sigma-Aldrich, Milan Italy) in endothelial cell growth medium EGM-2 Bullet Kit (Lonza-Euroclone) [24] . ECFCs are expressed as ECFCs frequency/10 7 MNC. Endothelial colonies were identify using a) morphological criteria; b) immunophenotypic analysis (fluorescence microscopy and flow cytometry). For immunofluorescence analysis, endothelial colonies were fixed with 4% paraformaldehyde, washed with phosphate-buffered saline (PBS) and then incubated with mouse antihuman CD31 (DakoCytomation, Milan, Italy).Goat anti mouse-Alexa Fluor 488 (Molecular Probes, Invitrogen S.R.L., Milan, Italy) conjugated antibodies was used as secondary antibodies and4',6'-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame,CA, USA) was used for nuclear counterstaining. Both cell morphology and green fluorescence were then analyzed by inverted fluorescent microscope (Axio Vert. A1, Carl Zeiss S.p.A., Milan Italy)
Immunophenotypic characterization was performed on expanded ECFC at P2-P3. The following monoclonal antibodies were used: CD14 and anti-CD45 (BD Biosciences) anti CD-31, anti-CD90 and anti-CD144 (BD Pharmigen), anti-CD34, anti CD73, anti-CD105, anti-CD133, anti-CD146 and anti-CD309 (KDR;MiltenyiBiotec). Stained cells were acquired by a MACSquant 1 Analyzer 10 (MiltenyiBiotec) and the multicolor analysis was performed using FlowJo software.
Statistical Analyses
Statistical analyses were performed using the GraphPad Prism 3.0 statistical platform. The Mann-Whitney test was used to compare the differences between preterm and term biological samples. All differences with p<0.05 were considered statistically significant. Data were expressed as median (range) for all the statistical analysis. Correlation analysis was performed using Pearson's Correlation r.
Results
Samples
Our study included 58 term (1 twin) and 50 preterm (11 twins) UCB samples; in the preterm group, 21/50 neonates had a gestational age of <32 wks.
Clinical data of pre-term infants, including birth weight, gestational age, gender, clinical problems after delivery and survival outcome are presented in Table 1 . Preterm neonates had a lower number of white blood cells (WBCx10 
CD34
We assessed whether preterm UCB leads to changes in the proportion of circulating total CD34 + cells. 
Colony number
The absolute number of total CFCs /10μL WCB as well asthe frequency of CFC/5x10 4 NC observedin the second generationresulted higher in preterm samples compared to term ones (p = 0.004 and p = 0.05 respectively; Table 3 ). In addition,the CFCs number /10μL WCBresulted inversely correlated with the gestational age of the neonates (Pearson r = -0.3001 p = 0.0168), although the number of cells for each colony was not affected by gestational age (p = 0.9).
All lineages were represented in culture with a prevalence of erythroid colonies (BFU-E) in the first and in the second generation ( Table 3 ). The re-plating efficiency of term CB resulted lower compared to preterm (68% vs 82% in secondary generation) and only pre-term samples (17%) could grow until the third generation. 
Endothelial cells
Colonies of endothelial cells (ECFCs) typically appeared between day +5 and day +14 and were identified as well-circumscribed monolayers of cobblestone-appearing cells which enlarged rapidly. These cells omogenously expressed CD31 antigen. A time-course picture of living ECFCs are show in Fig 3 . ) and expanded rapidly in culture: a median of 3.0 fold expansion in the number of endothelial cells from the first to the second generation (range 1.3-10.4) and a median of 2.6 fold expansion from the second to the third (range 0.9-8.4). No differences were observed between preterm and full-term CB (data not shown). ECFCs expressed typical endothelial markers (CD31, CD144, CD146) and CD73 (Table 4) .
CD34 antigen was present in the majority of the endothelial cells (> 75%) expanded in vitro and showed a range of expression from bright to dim both in preterm and term samples. A small percentage of CD34 + KDR + cells were also represented in ECFCs from both preterm and full term CB (Table 5) .
TaqMan 1 Gene Expression Assays
We have analyzed the expression of several genes, mainly related to stemness maintenance and cell differentiation in selected CD34+ cells (S1 Table) . Overall, the pattern of expression did not significantly differed between the two groups. Only a few genes were not expressed in fullterm CD34+ cells respect to preterm: NFIL3, ETS1, SET, PRDM1, and ID2. Several genes resulted differently over-expressed (as genes involved in the maintenance of self-renewal, stem cell reprogramming and pluripotency as well as genes essential in regulating the development and maintenance of hematopoiesis) in full term and in preterm progenitors but comparison between the two groups failed to identify statistically significant differences (S2 Fig) .
Discussion
In this study, we show that the proportion of total CD34 + cells in the cord blood of preterm neonates is higher compared to full term neonates and this difference is inversely correlated with gestational age: in fact, the highest proportion of CD34 + cells is found in samples from Table 4 . Analysis of the cell surface antigens of cord blood ECFCs from preterm and term neonates. [25] [26] [27] and genes related to the expansion of the hematopoietic stem cell pool (HOXB3, DPPA4) [28, 29] . We found that the majority of CD34+ cells co-express CD71 antigen (p<0.05 term vs preterm); this translate in a prevalent growth in vitro of large bursts [30] . Interestingly, in the second generation the vast majority of the colonies are erythroid. The prevalence of the erythroid lineage commitment within the CD34 + cell population and the capacity of these progenitors to growin secondary generation, is suggestive for the presence in cord blood of an immature progenitor devoid to transport oxygen, carbon dioxide and to facilitate vascular remodeling. These progenitor cells disappear very soon after birth [31, 8] . UCB from full term newborns exhibit a higher WBC count than UCB from preterm, but a lower HP concentration in keeping with a previous study [11] .This difference is inversely correlated with the gestational age, thus suggesting that circulating CD34 + cells do not substantially expand from the second to the third trimester of the fetal life or that this population undergoes expansion but leaves the circulation and progressively reaches the hematopoietic niches in the bone marrow. In fact, it has been demonstrated in the humans, that the vascular microenvironment reaches relative maturity by 20 th gestational week and that osteoblastic/ endosteal niche is completed later, when mesenchymal (endochondral) tissue became ossified [8] . Thus, it is possible that, a population of immature HP can persist into the blood stream of the preterm neonates before homing into a transient endothelial niche and finally into the trabecular bone, as demonstrated in the zebrafish model [32] . In our analysis, endothelial progenitor cells frequency (measured as ECFC) present in the cord blood did not show to be correlated with gestational age nor with maternal or neonatal characteristics. These data differ from other studies [18] which suggest that circulating endothelial progenitors are correlated with Bronchopulmonary Dysplasia (BPD) occurrence in preterm infants. These differences may be explained by the assay used: our data are based on functional studies and not on phenotypic analyses of whole cord blood.
ECFC grew in vitro large number of endothelial cells until the third generation that strongly expressed CD73, an ecto-5'-nucleotidase that convert adenosine triphosphate to adenosine, as well as CD31, CD34 and CD146, thus resembling a transitional phenotype between mesenchymal stem cells and endothelial progenitors. Usually, Endothelial-Mesenchymal Transition (EndMT) is considered a source for fibroblasts and myofibroblasts for cardiac development as well as, a pathologic condition occurring during tumor development and organ fibrosis. However, recent studies have found that EndMT cells also had 'stemness', which means they could differentiate into cells of multiple lineages [33] . In this contest, endothelial progenitors isolated and expanded in vitro from UCB, probably identify a populations of progenitors with high proliferative potential, immature phenotype (CD34 + KDR + CD45 -) and capable to differentiate toward endothelial cells, smooth muscle cells and fibroblasts [34] . Cell therapy is a promising opportunity of regenerative medicine that can be used to treat some complications related to prematurity as respiratory distress, neurological, gastrointestinal and ophthalmological diseases [17] . However, the therapeutic use of preterm cord blood has some limits: the first one is that it is considered "not elegible for donation" due to the scarce number of cells except in the autologous setting [35] . The second is that preterm CD34+ cells show impaired homing ability, at least in the NOD/SCID mouse model [14] ; these data do not still exclude that the re-infusion of hemopoietic progenitors with high proliferative potential, although not supporting a stable engraftment, may reduce the number of red cell transfusions in preterm babies [36] .In addition, as in the paper [14] mice were transplanted using enriched CD34+ cells, it may be possible the fraction CD34-of the SP can have a role to ameliorate the hematological parameters.
Finally, the presence, in the cord blood of preterm babies, of endothelial/mesenchymal stem cells with high proliferative potential makes this tissue an important autologous source of cells capable to migrate to the site of inflammation for healing damage tissues [37] or to produce microvesicles which can protect organs from oxidative stress [38] .
However, pre-clinical studies should clarify which therapeutic strategy may be more beneficial to prevent complications related to preterm birth: whether to infuse autologous fresh cord blood cells soon after delivery or to isolate and expand in vitro specific progenitor cells (HSC and/or endothelial) and re-infuse them at later time. 
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